New HIV Panel Aims to Advance Virology Research
The new test panel provides a single-tube, 2.5-hour workflow designed to enable detection down to 1,000 viral genome copies
CORALVILLE, Iowa (June 24, 2024) — Global genomics solutions provider, Integrated DNA Technologies (IDT), is bringing a new solution to address challenges researchers face in accelerating human immunodeficiency virus (HIV) drug discovery and research.
The company announced availability of the xGen HIV Amplicon Panel consisting of primers designed to cover 99.3 percent of the HIV genome. Powered by IDT’s xGen Amplicon Technology, the HIV panel provides a single-tube, two-step PCR amplification workflow that uses overlapping primer sets to obtain high levels of genome coverage from as low as 1,000 double-stranded viral genome copies.
“This launch represents one of the many ways IDT is continuing to innovate on its NGS portfolio, comprised of stand-alone library preparation, target enrichment, and normalization chemistries, as well as connected NGS solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms, and drug development research,” said Steven Henck, PhD, vice president, R&D at IDT.
Related: Four Decades of HIV Testing: Where Do We Stand?
“While the scientific community has learned a lot about HIV and the disease it causes, continued research is needed to help the millions of people whose health continues to be threatened by the global HIV/AIDS pandemic,” he said.
“We believe our xGen HIV Amplicon Panel provides an accessible option for researchers and will be foundational to unlocking future discoveries and advancing HIV research.”
The new panel offers a streamlined workflow that goes from sample to sequencer in 2.5 hours with up to 1,536 unique dual indexing primers (UDIs) for multiplexed sequencing. This predesigned xGen Amplicon Panel built with xGen Amplicon Technology includes amplicon tiling and creation of super amplicons to ensure comprehensive genome coverage across existing variant genomes and provide resistance to future viral mutations that may fall within a priming site, thus enabling future identification of novel variants.
- This press release was republished with permission from Integrated DNA Technologies